Advertisement
ARTV vs RADX
Which Stock Would AI Choose? Artiva Biotherapeutics (ARTV) vs. Radiopharm Theranostics (RADX) Stock Comparison
Key Takeaways
- Tickeron AI Verdict: Based on observable trend consistency, stability, and relative market positioning, Tickeron's AI currently favors RADX over ARTV, which faces elevated uncertainty after discontinuing its lead program.
- ARTV is a clinical-stage cell-therapy developer that recently halted its lead candidate, AlloNK, after two patient deaths in a Phase 2a trial, triggering a ~94% workforce reduction and a strategic-alternatives review.
- RADX is an early-stage radiopharmaceutical (theranostic) company developing precision-oncology diagnostics and therapies, with a pipeline of licensed platform technologies and an MD Anderson joint venture.
- Both are small-cap, pre-revenue biotech names with high risk, but ARTV's recent clinical setback has sharply weakened its momentum relative to RADX.
- For more detail on each name, visit the ARTV Major News and ARTV Today's Price Move pages, as well as the RADX Major News and RADX Today's Price Move pages.
- Explore curated, market-adaptive strategies on the Trending AI Robots page.
Introduction
Investors scanning the small-cap biotechnology space often weigh a diversified clinical pipeline against the concentrated risk of a single lead program. This stock comparison examines ARTV (Artiva Biotherapeutics, Inc.) and RADX (Radiopharm Theranostics Limited), two early-stage developers operating in distinct corners of precision medicine. Artiva is pursuing off-the-shelf natural killer (NK) cell therapies, while Radiopharm Theranostics is building a radiopharmaceutical platform for cancer detection and treatment. Both are pre-revenue and speculative, making their relative performance and market positioning instructive for traders and investors focused on catalysts, cash positions, and clinical-stage risk. The comparison is especially relevant in a market environment that has repriced many high-risk biotech names.
ARTV Overview and Recent Performance
ARTV, based in San Diego, is a clinical-stage biotechnology company developing allogeneic (donor-derived) natural killer (NK) cell therapies for autoimmune diseases and certain cancers. Its lead candidate, AlloNK, was being evaluated in combination with monoclonal antibodies across indications such as lupus and rheumatoid arthritis.
Recent market activity has been defined by a significant negative catalyst. The company announced it would discontinue development of AlloNK following two patient deaths in a Phase 2a trial, alongside a roughly 94% reduction in workforce and a review of strategic alternatives that could include a merger or asset sale. The stock fell sharply in response, and several sell-side analysts downgraded the name to neutral-equivalent ratings with materially lower price targets. Artiva's shares now trade well below their 52-week high, and the equity is priced near or below the company's reported per-share cash position, reflecting the market's repricing of its remaining value and the litigation and wind-down overhang tied to the discontinued program.
RADX Overview and Recent Performance
RADX, Radiopharm Theranostics Limited, is an Australian-incorporated research and development company advancing radiopharmaceutical products for both therapeutic and diagnostic (theranostic) applications in precision oncology. Its platform spans peptides, fatty acids, and antibody-based targets attached to medical radioisotopes, with a focus on radiosensitive solid tumors. The company maintains a portfolio of licensed platform technologies and a joint venture, Radiopharm Ventures LLC, with MD Anderson Cancer Center.
As a micro-cap, pre-revenue developer, RADX carries substantial clinical and financing risk, and its stock is highly sensitive to pipeline milestones and capital raises. In recent weeks, however, the company has not experienced the kind of single-program discontinuity that defined Artiva's period, and its narrative remains centered on building a multi-asset theranostic pipeline rather than on a single lead candidate. This broader pipeline structure, while still early stage, has supported relatively more stable market positioning in the comparison, even as the stock remains volatile and thinly traded.
Trending AI Robots
Tickeron's Trending AI Robots page is a curated selection of algorithmic trading bots chosen for their suitability to current market conditions. While Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, only a focused subset earns placement in this section. These bots differ widely in trading style, strategy, timeframe, performance statistics, and the specific set of tickers they monitor, with many featuring track records and win-rate figures that traders can review. For those comparing names like ARTV and RADX, exploring the Trending AI Robots page can provide an automated, data-driven perspective on how such stocks are being positioned in real time.
Head-to-Head Comparison
Although both ARTV and RADX are pre-revenue biotech companies, their risk profiles diverge sharply. Artiva's value proposition was concentrated in a single lead asset, AlloNK, which has now been discontinued, leaving the company to evaluate strategic alternatives. Radiopharm Theranostics, by contrast, operates a multi-asset radiopharmaceutical platform, which distributes pipeline risk across several programs rather than concentrating it in one molecule.
The sector exposure also differs: Artiva sits within cell therapy for autoimmune and hematologic disease, while Radiopharm operates in radiopharmaceuticals and theranostics for solid tumors. In terms of recent momentum, Artiva has experienced a sharp, negative repricing and multiple analyst downgrades, whereas Radiopharm has not faced a comparable single-event disruption. Neither company generates meaningful revenue, and both depend on successful clinical data and access to capital. Artiva's larger cash balance is offset by the uncertainty of how much of that cash will ultimately reach shareholders, while Radiopharm's smaller scale leaves it more exposed to dilution risk.
Tickeron AI Verdict
On the balance of observable factors, Tickeron's AI would currently favor RADX over ARTV. Artiva's trend consistency has been materially disrupted by the discontinuation of its lead program, a substantial workforce reduction, and an open-ended strategic review, all of which weaken its near-term stability and clarity of catalysts. Radiopharm Theranostics, while earlier stage and smaller in scale, retains an intact multi-asset pipeline without a comparable recent negative event, giving it relatively more stable positioning in this pairing. This assessment is probabilistic rather than definitive: both names carry significant clinical and financing risk, and outcomes will depend heavily on future data and capital-market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARTV is a Hold and RADX is a Hold.
ARTV's RSI Oscillator remains in oversold zone for 11 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for ARTV just turned positive on November 09, 2026. Looking at past instances where ARTV's MACD turned positive, the stock continued to rise in 17 of 21 cases over the following month. The odds of a continued upward trend are 81%.
Following a +2.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARTV advanced for three days, in 95 of 110 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
ARTV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARTV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for ARTV entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.584) is normal, around the industry mean (3.498). P/E Ratio (-1.285) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (81.301) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. ARTV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARTV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Momentum Indicator for RADX turns negative, indicating new downward trend
RADX saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator turned negative. In 42 of the 46 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RADX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for RADX entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RADX's RSI Oscillator exited the oversold zone, 6 of 8 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for RADX just turned positive on October 13, 2026. Looking at past instances where RADX's MACD turned positive, the stock continued to rise in 10 of 16 cases over the following month. The odds of a continued upward trend are 62%.
Following a +10.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where RADX advanced for three days, in 63 of 79 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.263) is normal, around the industry mean (3.498). P/E Ratio (-0.051) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (8.681) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. RADX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RADX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
| ARTV | RADX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 75% |
| Stochastic ODDS (%) | 1 day ago 85% | 1 day ago 71% |
| Momentum ODDS (%) | N/A | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 81% | 1 day ago 63% |
| TrendWeek ODDS (%) | 1 day ago 85% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 83% | 1 day ago 90% |
| Advances ODDS (%) | 3 days ago 86% | 6 days ago 80% |
| Declines ODDS (%) | 13 days ago 85% | 1 day ago 90% |
| BollingerBands ODDS (%) | 1 day ago 71% | N/A |
| Aroon ODDS (%) | 1 day ago 84% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARTV’s FA Score shows that 1 FA rating(s) are green while RADX’s FA Score has 1 green FA rating(s).
- ARTV’s FA Score: 1 green, 4 red.
- RADX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARTV’s TA Score shows that 5 TA indicator(s) are bullish while RADX’s TA Score has 4 bullish TA indicator(s).
- ARTV’s TA Score: 5 bullish, 2 bearish.
- RADX’s TA Score: 4 bullish, 3 bearish.
Price Growth
ARTV (@Biotechnology) experienced а -3.33% price change this week, while RADX (@Biotechnology) price change was -4.49% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
RADX is expected to report earnings on Dec 02, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ARTV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ARTV has been loosely correlated with RADX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ARTV jumps, then RADX could also see price increases.
| Ticker / NAME | Correlation To ARTV | 1D Price Change % | ||
|---|---|---|---|---|
| ARTV | 100% | +0.25% | ||
| RADX - ARTV | 44% Loosely correlated | -2.35% | ||
| KYTX - ARTV | 37% Loosely correlated | +0.79% | ||
| CELC - ARTV | 34% Loosely correlated | -4.07% | ||
| AURA - ARTV | 32% Poorly correlated | -0.52% | ||
| IRON - ARTV | 32% Poorly correlated | +2.88% | ||
More | ||||
RADX and
Correlation & Price change
A.I.dvisor indicates that over the last year, RADX has been loosely correlated with PCSA. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if RADX jumps, then PCSA could also see price increases.
| Ticker / NAME | Correlation To RADX | 1D Price Change % | ||
|---|---|---|---|---|
| RADX | 100% | -2.35% | ||
| PCSA - RADX | 49% Loosely correlated | N/A | ||
| ARTV - RADX | 44% Loosely correlated | +0.25% | ||
| VTGN - RADX | 33% Poorly correlated | +2.57% | ||
| CVKD - RADX | 31% Poorly correlated | +0.69% | ||
| FBIOP - RADX | 29% Poorly correlated | +0.64% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| QMNV | 25.85 | 0.31 | +1.22% |
| FT Vest Nasdaq-100 Moderate Buffer ETF - November (QMNV) | |||
| GEND | 13.71 | 0.04 | +0.32% |
| Genter Capital Dividend Income ETF (GEND) | |||
| SJNK | 24.12 | 0.04 | +0.17% |
| State Street SPDR Bloomberg Short Term High Yield Bond ETF (SJNK) | |||
| FLCO | 20.59 | 0.02 | +0.10% |
| Franklin Investment Grade Corporate ETF (FLCO) | |||
| SDOW | 23.70 | -0.35 | -1.46% |
| ProShares UltraPro Short Dow30 (SDOW) | |||